(New York Times) – U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.

The Food and Drug Administration has ordered producers and sellers of the less expensive products to wind down operations in the coming weeks now that it has declared there are no longer shortages of the blockbuster drugs Wegovy and Zepbound. (Read More)